Antisoma, a biotechnology company specializing in the development of novel drugs for the treatment of cancer, released a statement that the vaccine ASA404 improves anticancer responses and survival for patients with non-small cell lung cancer.

ASA404 is known as a vascular disrupting agent (VDA). ASA404 is different from angiogenenesis inhibitors that disrupt the new formation of blood vessels. This vaccine disrupts established blood vessels that feed cancer cells.

The researchers concluded that ASA404 appears promising in the treatment of advanced non-small cell lung cancer. A Phase III clinical trial is expected to begin in 2008. This is the last step prior to FDA review.

The Good Bead company wants you to show your support for the fight against breast cancer with their pink ribbon collection.

Here at The Good Bead we believe supporting the community never looked so good. We are focused on supporting worthy causes by custom creating high-quality, affordable products that engage consumers and raise awareness in the community.

The Good Beads new product Fondangles are quite possibly the most unique line of cell phone straps available. Their unique designs, high quality materials and optional o-ring make will attach to almost any cell phone. The Good Bead will be donating a percentage of sales from Fondangles to the Young Survival Coalition. Fondangles will be available beginning July 9th at Best Buys stores in New York City (Madison Avenue, Union Square, Noho, and 86th & Lexington); Riverside, CA (Tyler Street and Canyon Springs Parkway); Jacksonville, FL; Kennesaw, GA; Douglasville, GA; Atlanta, GA; and Peachtree, GA.

A German biotech company has announced positive results from a genetically engineered herpes virus that is designed to kill cancer cells. It not only kills the cancer cells but leaves healthy tissue unharmed. Results from clinical trials has showed promise.

Being injected with a virus might seem strange but researchers believe that viruses could one day become a valuable addition to conventional cancer treatments.

The results have shown in animal testing and limited human testing the ability to kill colorectal and liver cancer cells.

Liz Claiborne, fashion designer for working women climbing corporate ladders, died Tuesday at the New York Presbyterian Hospital after battling cancer for many years. She was 78.

Said Bill McComb, CEO of Claiborne's company since November: "In losing Liz Claiborne, we have not only lost the founder of our company, but an inspirational woman who revolutionized the fashion industry 30 years ago. Her commitment to style and design is ever present in our thinking and the way we work. We will remember Liz for her vision, her entrepreneurial spirit and her enduring compassion and generosity."

Claiborne, with husband Art Ostenberg and partners Leonard Boxer and Jerome Chazen, launched her label in 1976 after working for years as an unknown dress designer. Her brand featured ensemble sportswear with price tags below that of other designers and revolutionized the department store industry. Once compartmentalized, with pants in one department and skirts in another, Claiborne's coordinated clothing inspired the merging of once-separate departments.

Staff Sgt. Elizabeth Cowie's dream almost ended when she was diagnosed with breast cancer in May. She was told earlier in the year that she would deploy to Iraq this summer.

The forty-two year old mother is ready for duty after her aggressive treatment plan. She had two surgeries and a five day targeted radiation treatment called MammoSite. Elizabeth will leave later this month with the 1113th Transportation Company of San Jose, California, for at least a year transporting supplies in Iraq.

Elizabeth's mother Pearl said she "isn't surprised that her daughter still wants to deploy. I knew this would not deter her. She was just determined to go. That is the kind of person she is."

Alex's Lemonade Stand Foundation is all about the fight against childhood cancer. Tasty Baking Company is joining forces with Alex's Foundation by creating a new product called Alex's Lemon Krimpets. The Krimpets can be purchased anywhere Tastykakes are sold. The baking company will donate $.50 from every box sold to the foundation.

Alex Scott was four years old when she opened up her first lemonade stand to help raise money for Children's Hospital of Philadelphia. Sadly, Alex passed away in 2004 at the age of eight. But her legacy still lives on.

For more information about Alex's foundation you can go to www.alexslemonade.org. You can also visit http://www.tastykake.com to purchase some yummy Alex Lemon Krimpets and help the fight against childhood cancer.

We cannot be silent is one slogan printed on specialty clothing offered by a company called Privacy. Other slogans include United We Cure and Mission. Purpose. Cure.

The slogans say a lot -- but the accomplishments of Carolyn Jones, Founder and President/CEO of Privacy, say a whole lot more.

Think about this:

Jones lost her mother to breast cancer on November 16, 2000 during a time when too many questions about the disease were left unanswered and not enough options were available for women fighting for their lives.

Times have changed, in part due to outspoken pioneers like Jones, who are spreading the word and funding the cause.

Part of the Privacy corporate goal is to support medical research and to educate women about early detection and treatment.

"It is very clear that more information and research is needed due to the yearly increase in new cases nationally," says Jones who cites statistics such as this: every 12 minutes a woman in America will die from complications associated with breast cancer. And this: more than 1,500 new cases of male breast cancer will be diagnosed this year.

Privacy, a California-based company with a social conscious, offers for both women and men an assortment of t-shirts, sweatshirts, jeans, hats, recommended books, accessories, breast cancer facts, and even a contest or two. A portion of all profits are donated to breast cancer initiatives with an emphasis on low-income and uninsured populations.

Check it all out right here.

Wyeth officials say their hormone replacement therapy Prempro is not the cause of one Ohio woman's breast cancer. But two jury decisions prove otherwise.

The first jury, in October, awarded Jennie Nelson and her husband $1.5 million in compensatory damages, validating Nelson's claim that her breast cancer -- resulting in a double mastectomy, chemotherapy, and radiation -- was caused by the Prempro she took for six years. When this verdict was thrown out due to a mistrial, a retrial began.

The retrial concluded yesterday -- with a Philadelphia jury awarding the Nelsons this time with $3 million.

"Both times this case has been heard on terms established by Wyeth and still the juries have clearly found that Prempro causes breast cancer," says Nelson's attorney Tobias Millrood, adding that Wyeth puts sales ahead of patient safety.

Wyeth respectfully disagrees and argues that it acted responsibly in the promotion of its hormone replacement products and in disclosing with doctors and patients all therapy-associated health risks.

Millions of women have used Wyeth's hormone replacement therapies to control the effects of menopause, and the company, sanctioned in January to pay $1 million to an Arkansas breast cancer survivor, now faces more than 5,000 lawsuits of this same nature.

Despite a large-scale study revealing drugs like Prempro increase the risk of breast cancer if used for five years or more, the drug still remains on the market. And Wyeth is so sure their drug is not at fault for causing Nelson's breast cancer that they plan to appeal yesterday's verdict.

International pharmaceutical company AstraZeneca is donating $10 million to the American Cancer Society (ACS). The donation is one of the largest gifts ever received by the ACS and will help provide support for patients in United States hospitals.

Support will come in the form of specially-trained ACS employees who will work in 60 different hospitals and cancer centers and will offer social, emotional, financial, and transportation assistance in medically underserved Atlanta areas.

London-based AstraZeneca, maker of breast cancer drug tamoxifen and other breast and prostate cancer drugs, made $26 billion in sales last year, the same year the company gave $7 million to a Boston Cancer Society for the development of a Hope Lodge.

Women with early stage breast cancer now have a new tool at their disposal. The tool -- called MammaPrint -- is newly approved by the FDA and while it is not yet a perfect measure, it can be used along with other information to estimate whether breast cancer is likely to return in five or 10 years.

The value of this test, that measures through computer analysis the activity of 70 genes using a sample of tissue removed from a breast tumor, is that doctors and patients can better determine course of treatments.

MammoPrint offers two results -- high risk and low risk -- and accurately picked in studies which women were at low risk at least 90 percent of the time. However, for women who were told they were at high risk for recurrence as a result of the test, just 23 percent experienced a relapse.

"You can't go all the way to the bank with this test," says FDA official Dr. Steven Gutman who argues the test is still better than having no information at all.

Agendia, the Dutch maker of MammoPrint, is exploring ways to make this one-of-a-kind product available in the United States. It has been used in the Netherlands since 2005.

"This test has enormous implications for the short-term future of cancer research in general, and is one of the truly great breakthroughs of our time," says Cancer Blog reader Gregory Pawelski with whom I am grateful for sharing this story tip with me.

I am headed out the door this Christmas morning -- with my husband and two little boys -- to my sister's house where our family members will gather to celebrate the spirit of the season. There will be good food and good company and good laughs -- and good gifts too. And while I have managed to create a mini wish list -- I'm liking decorative tin stars this year and I'll always take the gift of a pedicure -- there is only one gift I really want. Time.

I have been surviving breast cancer for two years. I've seen my oldest child march off to kindergarten and my youngest son grow into an independent little soul. I've seen my hair grow, my anxiety diminish, and my writing career blossom. Time is quite a gift. And I want more of it.

I want to see my kids tackle first grade and preschool. I want to further develop my writing pursuits. And I want meet my sister's new baby, due at the end of May.

I believe in my head and my heart and my gut that I have a lot more time left on this planet. But just to be safe, I'm keeping time on my wish list for as long as I can. Because all ll I really want for Christmas -- every Christmas -- is time.

Tampa's H. Lee Moffitt Cancer Center & Research Institute, the only comprehensive cancer center in Florida, has just partnered with Merck & Co., one of the world's largest drug companies, to develop personalized cancer treatments using a patient's genetic profile.

The two powerhouse entities will form a for-profit company called M2Gen on donated land near the University of South Florida. And in the span of just a few years, researchers plan to compile a database of tumor tissue and other medical information to determine why some patients respond to treatment while others do not. The database could house information on more than 30,000 patients within five years and will enable researchers to identify biological markers that could help doctors choose the most effective treatment based on the genetic make-up of each patient's tumor.

Blind treatment -- where everyone receives the same thing -- will be a thing of the past as tailor-made therapies replace the one-size-fits-all approach.

Florida Governor Jeb Bush says of the partnership that will create more than 170 high-paying jobs, "Man, I don't know if you can think of a better Christmas present than that."

Deep within the pages of ancient texts detailing the remedies used by Chinese medicine practitioners, is there a cure for cancer waiting to be rediscovered? The global pharmaceutical company Merck thinks there might be a reference or two to natural cancer-fighting products used by healers then that is obscurely hidden and not known now in modern western medicine.

Merck has entered into a deal with Hong Kong's Chi-Med to look for evidence of promising products that the pharmaceutical company can research and test in clinical trials. According to the article Merck looks for ancient Chinese cancer cure written by Susie Mesure, "Western pharmaceutical companies are increasingly outsourcing their drug discovery work, with many looking east for the solution to medical mysteries that Western doctors cannot solve."

Traditional Chinese Medicine, TCM, is a practice of medicine that combines medicinal herbs, nutrition, meditation, massage, exercise and acupuncture with an applied philosophy in the harmonious balance of yin and yang for treating illness. In all fairness, because this system of medicine has developed over thousands of years, and my understanding limited by Western educational influence, the definition I have given is a very brief, and possibly incomplete, overview of TCM. If you are interested in learning more about TCM, begin by visiting Traditional Chinese Medicine at Wikipedia.

Chi-Med will be scanning information in a library of 10,000 natural substances for those that might hold potential in a cure for cancer. It will be interesting what they find.

The Susan G. Komen Breast Cancer Foundation wants help fighting breast cancer. So forget about fighting crowds this holiday season -- help fight cancer instead.

The Komen Marketplace is offering two specially designed holiday greeting cards this year, available for purchase on-line through December 8.

Prices for cards, that can be personalized with an individual name, a company name, and a special message, range depending on the card. One option costs $1.30 to $1.40 per card, plus nominal printing fees. Another option costs $5.00 per card, with no printing fees. For this option, The Komen Foundation will also print envelopes with mailing and return addresses. They will even stamp envelopes and drop the cards in the mail too.

Fifty to 100 percent of sales will benefit the fight against breast cancer. And 100 percent of the cards will spread hope and promise through messages like this -- The best gifts are wrapped in the joy we give to others. Happy Holidays. This card has been given to you as a special tribute in support of the Susan G. Komen Breast Cancer Foundation.

Teenager Abraham Cherrix made national headlines recently with a legal battle that earned him the right to fight cancer on his own terms. Cherrix, 16, who chose to treat his disease with alternative treatments after traditional therapy failed to cure him of Hodgkin's disease, was told by the courts that his choice was not acceptable -- that he must undergo higher doses of chemotherapy in combination with radiation and followed by stem cell transplant. Cherrix ended up a winner in court and is currently receiving the therapy of his choice. But despite the legal win, Cherrix and his family are losing financially.

The Cherrix family owns a kayak company in Virginia, and spring and summer are peak seasons. Since the family had to close shop on many occasions due to court appearances, profits suffered. So on Sunday afternoon, local musicians headlined a fundraising concert -- billed as Voices for Choices -- to help with medical and court costs. Cherrix could not attend -- he's in the midst of treatment in Mississippi -- but the show went on. And while the money raised is not enough to cover all outstanding bills, it is enough to remind the family of all the caring people in the world.

Reports from family indicate Cherrix is doing well with treatment and that his tumor is shrinking. If he continues to make progress, he may be able to return home soon -- so he can thank those whose support is so much more than money can buy.